11 studies on Dsip curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab indexes 1,046 published Dsip COA source records from third-party laboratories, covering 453 publicly attributable vendor identities. Across 924 records with positive numeric purity, the arithmetic mean is 99.25%. 0 records report zero purity; these remain in the record count and are excluded from the positive-purity mean. 2 positive purity results are below 90%; 76 records report measured amount more than 10% below the label. The latest recorded test date is 2026-10-10. TitrateLab did not perform these laboratory tests. Source records are not unique batches, and vendor identity does not establish manufacturing role, product safety or overall quality.
As of 2026-10-18, vendor-blind retail asking-price averages for the US delivery market, calculated from the same in-stock exact-strength cells as the Peptide Price Index. Shipping is excluded.
| Strength | Average / vial | Observed range / vial | Average / mg | Coverage |
|---|---|---|---|---|
| 2 mg | $5.50 | $5.50–$5.50 | $2.75 | 1 source · 1 offer |
| 5 mg | $7.50 | $6.50–$8.00 | $1.50 | 3 sources · 3 offers |
| 10 mg | $10.67 | $10.00–$11.50 | $1.07 | 3 sources · 3 offers |
| 15 mg | $13.00 | $13.00–$13.00 | $0.87 | 1 source · 1 offer |
Asking prices are not manufacturing cost and do not establish product equivalence, quality, safety, or legality. View full price methodology →
All published source records, including absent and zero purity. Matching uses a case-insensitive exact peptide token. No deduplication in the headline; vendor rankings deduplicate eligible certificates separately. The COA archive can use normalized compound names and a different measurement or duplicate policy; totals from these populations need not match.
Latest recorded test: 2026-10-10. Aggregate calculated: 2026-10-18T15:38:14.697239+00:00. Calculation time is not a laboratory observation date.
Within that total, 249 source records have unresolved vendor identity. They remain in corpus-level lab evidence and are excluded from named-vendor rankings.
Eligible vendors have at least 2 deduplicated certificates and 2 classifiable identity observations. Rank uses the 95% lower confidence bound on clean identity results; mean positive purity and certificate count break ties. Missing measurements are not passes. Exact-zero/not-detected and explicit wrong-compound markers count once per adverse certificate. This describes submitted-sample evidence, not every product or shipment, and is not an endorsement.
| Rank | Vendor | Deduplicated certificates | Avg positive purity | Identity adverse results | |
|---|---|---|---|---|---|
| #1 | 23 | 99.5% | 0 of 19 (0.0%) 0 0% / not detected · 0 wrong compound · 4 unclassified | Reveal with Pro → | |
| #2 | 16 | 99.63% | 0 of 16 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → | |
| #3 | 11 | 99.09% | 0 of 11 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → |
Vendor identities are included with Pro. Record counts and lab measurements remain visible.
Recent source records: #119189 (99.16%) · #118991 (99.0%) · #118913 (99.0%) · #118866 (99.25%) · #118808 (99.52%) · #119492 (99.35%)
For **automotive engineers and system designers**, optimizing FlexRay message scheduling is critical for ensuring the stability and real-time performance of intelligent connected vehicles. Improved bandwidth utilizati…
This review highlights that polyamines represent a significant and underexplored therapeutic avenue for addressing cognitive impairment in various neurological and psychiatric conditions. Understanding their complex m…
These findings are significant as they highlight delta sleep-inducing peptide (DSIP) as a potential therapeutic agent for mitigating stress-induced liver damage and dysfunction. The observed normalization of oxidative…
This research highlights the hepatoprotective potential of Delta Sleep-Inducing Peptide (DSIP), particularly in mitigating liver damage caused by chronic psychological stress. The findings suggest that DSIP could be a…
This study presents a proof-of-concept for enhancing the therapeutic properties of DSIP through protein fusion engineering. By combining DSIP with human serum albumin and a protein transduction domain, the researchers…
This research provides a mechanism-backed rationale for using p-DSIP to mitigate cognitive decline caused by high-altitude environments. For individuals operating at altitude (mountaineers, aviators, military personne…
This research significantly advances our understanding of the fundamental molecular mechanisms underlying precise neural circuit formation. By identifying DIP-α and Dpr10 as key transsynaptic organizers, the study pro…
This research represents a significant advancement in sustainable peptide chemistry, providing a greener and more efficient route for producing peptide pharmaceuticals and biomaterials. By drastically reducing chemica…
Free, no account — handy when you're working with Dsip.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$14 monthly or $88/year
Create an account